Trevi Therapeutics Inc (TRVI) Stock Price, Quote & News

Company Profile

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough i...

Industry: Biotechnology

Sector: Healthcare

Phone: 203 304 2499

Website: www.trevitherapeutics.com

Address:

195 Church Street, 16th Floor, New Haven, United States

jlcrane Mar. 19 at 3:26 PM

$TRVI Now we are going to correlate to the indexes? WTF!

0 · Reply

jlcrane Mar. 18 at 1:40 PM

$TRVI Someone explain to me what the incentive is to sell this stock?

1 · Reply

jlcrane Mar. 18 at 1:33 PM

$TRVI Is this fucked up or what? Trades up to 12 and then they smash it. Even though there are upgrades. Manipulation at its best.

0 · Reply

Quantumup Mar. 18 at 11:26 AM

Cantor reiterated $TRVI Overweight; $25 after TRVI reported 4Q earnings. VRNA - $MRK $GSK Cantor said:::Initiation of multiple late-stage studies of Haduvio for IPF chronic cough, RCC, and non-IPF ILD chronic cough are expected this year. TRVI has become a preferred name for a number of specialist investors. The consistently strong efficacy and safety profile across multiple P2 studies provides confidence in P3 trial outcomes. Feedback from KOLs regarding Haduvio's profile and role in treating cough in various settings has been very strong. The unmet need across indications is high and can support peak sales in the multi-billion dollar/yr range. Questions about IP and perception of a mixed opioid agonist/antagonist have generally been addressed.

1 · Reply

erevnon Mar. 18 at 11:14 AM

Needham maintains Trevi Therapeutics $TRVI at Buy and raises the price target from $22 to https://marketsblock.com/stock-upgrades-and-downgrades/

1 · Reply

anachartanalyst Mar. 18 at 11:02 AM

$TRVI https://anachart.com/wp-content/uploads/ana_temp/1773831669_soc-img.jpg

0 · Reply

hmandude Mar. 18 at 10:19 AM

$TRVI Not much on this board nowadays. But the CC yesterday seemed like deliberate progress is being made. The only negative nugget was that they stated that their cash would not get them thru all their phase 2s (ILD and RCC) and the two phase 3s for IPF. So there is likely going to be one more raise to get thru all the readouts. Otherwise their trials seem aligned with the FDA, with clear established endpoints. Lots of analyst questions and interest. Management continues to sound well-prepared and intelligent. I think it was a sound decision to run the two phase 3s as they can’t bank on the FDA delivering on their “one phase 3 trial” initiative. Overall I remain willing to hold patiently until results 2028 in my long term account.

0 · Reply

StocktwitsEarnings Mar. 17 at 9:21 PM

$TRVI Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.06 up 45.45% YoY • Trevi Therapeutics expects existing cash, cash equivalents, and marketable securities of $188.3M as of December 31, 2025, to fund operating expenses and capital expenditure requirements into 2028.

0 · Reply

DonCorleone77 Mar. 17 at 8:39 PM

$TRVI Trevi Therapeutics reports Q4 EPS (6c), consensus (10c) The company ended 2025 with $188.3M with expected cash runway into 2028. "Our progress in 2025 marked a major inflection point for Trevi's growth trajectory, driven by positive Phase 2 data across our chronic cough programs," said Jennifer Good, President and CEO of Trevi Therapeutics. "These results provide a strong foundation as we pursue our goal of becoming a leader in treating chronic cough. We've carried this momentum into 2026 as we gained overall alignment with the FDA during our End-of-Phase 2 meeting for patients with IPF-related chronic cough. We are now focused on initiating the first of our two pivotal Phase 3 IPF-related chronic cough trials, as well as our Phase 2b RCC trial in the second quarter of this year. Looking ahead, Trevi is well positioned to execute on its clinical programs and help address the high unmet need for patients who are burdened by chronic cough in our target indications, where there are no FDA-approved therapies."

0 · Reply

jlcrane Mar. 12 at 2:18 PM

$TRVI Down 5% on 95k shares? What a bunch of idiots.

0 · Reply

Trevi Therapeutics, Inc. (TRVI) Q4 2025 Earnings Call Transcript

Mar 17, 2026, 4:05 PM EDT - 4 days ago

Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates

Mar 10, 2026, 4:05 PM EDT - 11 days ago

Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026

Mar 9, 2026, 7:30 AM EDT - 12 days ago

Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough

Mar 2, 2026, 7:30 AM EST - 19 days ago

Trevi Therapeutics to Participate in Upcoming March Conferences

Feb 17, 2026, 7:30 AM EST - 4 weeks ago

Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Jan 22, 2026, 12:30 PM EST - 2 months ago

Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)

Jan 8, 2026, 7:30 AM EST - 2 months ago

Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

Dec 4, 2025, 7:30 AM EST - 3 months ago

Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer

Dec 3, 2025, 2:16 PM EST - 3 months ago

Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And Beyond

Nov 13, 2025, 9:21 PM EST - 4 months ago

Trevi Therapeutics, Inc. (TRVI) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 4:05 PM EST - 4 months ago

Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 6, 2025, 4:05 PM EST - 4 months ago

Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025

Nov 4, 2025, 7:30 AM EST - 4 months ago

Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference

Oct 8, 2025, 7:30 AM EDT - 5 months ago

Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting

Sep 18, 2025, 7:30 AM EDT - 6 months ago

Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025

Sep 9, 2025, 7:15 PM EDT - 6 months ago

Trevi Therapeutics, Inc. (TRVI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Aug 28, 2025, 7:30 AM EDT - 7 months ago

Trevi Therapeutics to Participate in Upcoming September Conferences

Aug 8, 2025, 1:47 PM EDT - 8 months ago

Trevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 8 months ago

Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 31, 2025, 4:05 PM EDT - 8 months ago

Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025

Jul 29, 2025, 7:30 AM EDT - 8 months ago

Trevi Therapeutics to Participate in Upcoming August Conferences

Jul 1, 2025, 7:30 AM EDT - 9 months ago

Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism

Jun 5, 2025, 4:30 PM EDT - 10 months ago

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Jun 3, 2025, 10:15 PM EDT - 10 months ago

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

Jun 2, 2025, 4:01 PM EDT - 10 months ago

Trevi Therapeutics Announces Proposed Public Offering of Common Stock

Jun 2, 2025, 1:42 PM EDT - 10 months ago

Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients

Jun 2, 2025, 7:00 AM EDT - 10 months ago

Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

Jun 1, 2025, 4:00 PM EDT - 10 months ago

Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

May 29, 2025, 7:30 AM EDT - 10 months ago

Trevi Therapeutics to Participate in Upcoming June Conferences

$Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough$

May 20, 2025, 7:00 AM EDT - 10 months ago

Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

May 11, 2025, 4:16 AM EDT - 11 months ago

Trevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 11 months ago

Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 1, 2025, 4:05 PM EDT - 11 months ago

Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025

Apr 3, 2025, 7:30 AM EDT - 1 year ago

Trevi Therapeutics to Participate in Upcoming April Investor Conferences

Mar 18, 2025, 6:47 PM EDT - 1 year ago

Trevi Therapeutics, Inc. (TRVI) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 4:05 PM EDT - 1 year ago

Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates

Mar 11, 2025, 4:05 PM EDT - 1 year ago

Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025

Mar 10, 2025, 11:30 AM EDT - 1 year ago

Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps

$Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough$

Mar 10, 2025, 6:00 AM EDT - 1 year ago

Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

$Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough$

Mar 9, 2025, 4:00 PM EDT - 1 year ago

Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Feb 27, 2025, 7:30 AM EST - 1 year ago

Trevi Therapeutics to Participate in Upcoming March Investor Conferences

Feb 25, 2025, 7:30 AM EST - 1 year ago

Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Jan 30, 2025, 7:30 AM EST - 1 year ago

Trevi Therapeutics to Participate in Upcoming February Investor Conferences

Jan 8, 2025, 7:30 AM EST - 1 year ago

Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

Dec 16, 2024, 7:36 AM EST - 1 year ago

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering

Dec 12, 2024, 9:47 AM EST - 1 year ago

Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?

Dec 12, 2024, 7:30 AM EST - 1 year ago

Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Dec 3, 2024, 4:05 PM EST - 1 year ago

Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine

jlcrane Mar. 19 at 3:26 PM

$TRVI Now we are going to correlate to the indexes? WTF!

0 · Reply

jlcrane Mar. 18 at 1:40 PM

$TRVI Someone explain to me what the incentive is to sell this stock?

1 · Reply

jlcrane Mar. 18 at 1:33 PM

$TRVI Is this fucked up or what? Trades up to 12 and then they smash it. Even though there are upgrades. Manipulation at its best.

0 · Reply

Quantumup Mar. 18 at 11:26 AM

1 · Reply

erevnon Mar. 18 at 11:14 AM

Needham maintains Trevi Therapeutics $TRVI at Buy and raises the price target from $22 to https://marketsblock.com/stock-upgrades-and-downgrades/

1 · Reply

anachartanalyst Mar. 18 at 11:02 AM

$TRVI https://anachart.com/wp-content/uploads/ana_temp/1773831669_soc-img.jpg

0 · Reply

hmandude Mar. 18 at 10:19 AM

0 · Reply

StocktwitsEarnings Mar. 17 at 9:21 PM

0 · Reply

DonCorleone77 Mar. 17 at 8:39 PM

0 · Reply

jlcrane Mar. 12 at 2:18 PM

$TRVI Down 5% on 95k shares? What a bunch of idiots.

0 · Reply

abcdzepeda Mar. 11 at 3:29 PM

$TRVI now I know the reason for the price drop, we are 2 1/2 years away from an approval. Oh well, I guess I will just keep adding until we get approved.

1 · Reply

OfficialStocktwitsUser Mar. 10 at 4:50 PM

$TRVI RSI: 63.04, MACD: 0.3482 Vol: 0.94, MA20: 11.49, MA50: 11.32 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

jlcrane Mar. 10 at 4:00 PM

$TRVI Fucking company. Time and again they kill the rally.

1 · Reply

thefourpercent Mar. 10 at 12:18 PM

$TRVI still not concerned

0 · Reply

thefourpercent Mar. 9 at 11:01 PM

$TRVI will exit tomorrow probably around 3% profit. Expect it to do better though.

0 · Reply

focafoca99 Mar. 9 at 9:51 PM

$TRVI Phase 1, 2, and 3 references all showed up

0 · Reply

mikesterz7 Mar. 9 at 9:28 PM

$TRVI The company also said that it has secured FDA alignment on the remaining early-stage trials needed to support an application to the agency seeking approval.

0 · Reply

StocktwitsNews Mar. 9 at 8:54 PM

TRVI Stock Slips After Company Plans Parallel Trials In Lung Disease — Stifel Dismisses Timeline Concerns $TRVI $IWM $VXF https://stocktwits.com/news/equity/markets/trvi-stock-slips-after-company-plans-parallel-trials-in-lung-disease/cZdVDFCRIeE

0 · Reply

notreload_ai Mar. 9 at 7:34 PM

$TRVI shares plunged despite positive FDA alignment for Haduvio in IPF chronic cough. Plans for two Phase 3 trials (instead of one) triggered sell-off; Stifel holds Buy rating on the de-risked program. https://notreload.xyz/fda-clears-path-for-haduvio-but-trevi-safe-two-trial-plan-sends-trvi-down/

1 · Reply

medguy Mar. 9 at 6:20 PM

Looking for bounce $OLMA $ORIC $TRVI $BRAI

0 · Reply

thefourpercent Mar. 9 at 4:30 PM

$TRVI likely news will reflect after hours or pre market tomorrow. I’m In for a couple percent come back tomorrow

0 · Reply

abcdzepeda Mar. 9 at 4:01 PM

$TRVI interesting, we are down today after learning that the FDA meeting went well!

0 · Reply

Market Cap	1.37B
Revenue (ttm)	0.00
Net Income (ttm)	-47.91M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,296,800
Avg Vol	1,366,650
Day's Range	N/A - N/A
Shares Out	128.23M
Stochastic %K	13%
Beta	0.94
Analysts	Strong Sell
Price Target	$21.58